Clinical Trials Logo

Male Breast Cancer clinical trials

View clinical trials related to Male Breast Cancer.

Filter by:

NCT ID: NCT00096434 Completed - Clinical trials for Stage IV Breast Cancer

Sorafenib in Treating Patients With Metastatic Breast Cancer

Start date: September 2004
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well sorafenib works in treating patients with metastatic breast cancer. Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor.

NCT ID: NCT00095888 Terminated - Clinical trials for Stage IV Breast Cancer

3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer

Start date: October 2004
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of combining 3-AP with gemcitabine in treating patients who have refractory metastatic breast cancer. Drugs used in chemotherapy, such as 3-AP and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining 3-AP with gemcitabine may kill more tumor cells

NCT ID: NCT00089362 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors

Start date: July 2004
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of alvespimycin hydrochloride in treating patients with metastatic or unresectable solid tumors. Drugs used in chemotherapy, such as alvespimycin hydrochloride, work in different ways to stop tumor cells from dividing so they stop growing or die.

NCT ID: NCT00077376 Completed - Clinical trials for HER2-positive Breast Cancer

Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer

Start date: March 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well giving trastuzumab together with ixabepilone and carboplatin works in treating patients with HER2/neu-positive metastatic breast cancer. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as ixabepilone and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining trastuzumab with ixabepilone and carboplatin may kill more tumor cells.

NCT ID: NCT00071942 Terminated - Clinical trials for Stage IV Breast Cancer

Vaccine Therapy in Treating Patients With Metastatic Breast Cancer

Start date: October 2003
Phase: Phase 1
Study type: Interventional

Vaccines may make the body build an immune response to kill tumor cells. This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with metastatic breast cancer.

NCT ID: NCT00068588 Completed - Clinical trials for Stage IV Breast Cancer

GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer

Start date: October 2003
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well giving GTI-2040 together with capecitabine works in treating patients with metastatic breast cancer. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. GTI-2040 may help capecitabine kill more tumor cells by making them more sensitive to the drug

NCT ID: NCT00063934 Terminated - Clinical trials for Stage IV Breast Cancer

Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Start date: May 2003
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial is studying the side effects and best dose of oblimersen when given together with doxorubicin and docetaxel and to see how well they work in treating women with metastatic or locally advanced breast cancer. Drugs used in chemotherapy, such as doxorubicin and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of doxorubicin and docetaxel by making the tumor cells more sensitive to the drugs.

NCT ID: NCT00045188 Completed - Clinical trials for Stage IV Breast Cancer

Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer

Start date: August 2002
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have metastatic breast cancer. Imatinib mesylate may stop the growth of cancer by blocking the enzymes necessary for tumor cell growth

NCT ID: NCT00039455 Terminated - Clinical trials for HER2-positive Breast Cancer

Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer

Start date: April 2002
Phase: Phase 1
Study type: Interventional

Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining trastuzumab with flavopiridol may kill more tumor cells. Phase I trial to study the effectiveness of combining trastuzumab with flavopiridol in treating patients who have metastatic breast cancer

NCT ID: NCT00030615 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Decitabine in Treating Patients With Advanced Solid Tumors

Start date: December 2001
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of decitabine in treating patients with advanced solid tumors that have not responded to previous treatment. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die